Application status of endoscopic anti-reflux mucosal interventions in the treatment of gastroesophageal reflux disease

Table 2 Anti-reflux mucosal ablation or peroral endoscopic cardial constriction treatment for gastroesophageal reflux disease has shown favorable outcomes, %

Ref.	Year	Intervention	Cases	Effective rate	PPI usage
					Discontinuation	Reduction
Inoue et al[19]	2020	ARMA	8	100	62.5	37.5
Hernández Mondragón et al[20]	2020	ARAT	108	94.3	78.6	15.7
Chou et al[22]	2023	ARMA	12	73.9	56.5	NA
Shimamura et al[23]	2024	ARMA	68	70	43.4	NA
Klimczak et al[24]	2023	ARMA	10	86.7	73.3	NA
Average				84.98	62.86	26.60
Li et al[25]	2017	PECC	47	73.7	NA	NA
Liu et al[26]	2020	C-BLART	60	43	43	NA
Seleem et al[27]	2018	EBL	75	65	65	NA
Li et al[28]	2021	PECC-b	68	77.9	77.9	NA
Jiang et al[29]	2022	PECC-b	16	62.5	NA	NA
Deshmukh et al[30]	2022	ARBM	4	100	100	NA
Hu et al[34]	2018	PECC	13	69	NA	NA
Wang et al[39]	2020	PECC	15	100	93.3	6.7
Average				73.89	75.84	6.70

ARMA: Anti-reflux mucosal ablation; ARAT: Anti-reflux ablation therapy; PECC: Peroral endoscopic cardial constriction; EBL: Endoscopic band ligation; C-BLART: Clip band ligation anti-reflux therapy; PECC-b: Peroral endoscopic cardial constriction with band ligation; ARBM: Anti-reflux band mucosectomy; PPI: Proton pump inhibitor; NA: Not available.